CA2433227A1 - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy Download PDF

Info

Publication number
CA2433227A1
CA2433227A1 CA002433227A CA2433227A CA2433227A1 CA 2433227 A1 CA2433227 A1 CA 2433227A1 CA 002433227 A CA002433227 A CA 002433227A CA 2433227 A CA2433227 A CA 2433227A CA 2433227 A1 CA2433227 A1 CA 2433227A1
Authority
CA
Canada
Prior art keywords
polypeptide
peptide
cell
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002433227A
Other languages
English (en)
French (fr)
Inventor
Yocheved Hagay
Janette Lazarovits
Rachel Guy
Orly Lifschitz
Esther Szanton
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2433227A1 publication Critical patent/CA2433227A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002433227A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy Abandoned CA2433227A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
CA2433227A1 true CA2433227A1 (en) 2002-08-01

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002433227A Abandoned CA2433227A1 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (pt)
JP (1) JP2004524023A (pt)
KR (1) KR20030091952A (pt)
CN (1) CN100374456C (pt)
AU (1) AU2002246737B2 (pt)
BR (1) BR0116763A (pt)
CA (1) CA2433227A1 (pt)
CZ (1) CZ20031983A3 (pt)
HU (1) HUP0400775A2 (pt)
IL (1) IL156690A0 (pt)
MX (1) MXPA03005944A (pt)
NZ (1) NZ527173A (pt)
PL (1) PL365758A1 (pt)
RU (1) RU2316564C2 (pt)
WO (1) WO2002059264A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374431A1 (en) * 2002-07-01 2005-10-17 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN110437320B (zh) * 2010-07-09 2023-10-20 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
BR122020006914B8 (pt) * 2014-10-23 2023-01-31 Singh Biotechnology Llc Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108290940B (zh) * 2015-10-01 2021-12-07 圣拉斐尔医院有限公司 Tcr及其用途
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN109843325B (zh) * 2016-09-14 2023-10-03 特尼奥生物股份有限公司 Cd3结合抗体
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
CA2278106C (en) * 1997-01-22 2005-04-12 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
MXPA03005944A (es) 2005-04-29
WO2002059264A2 (en) 2002-08-01
RU2003123100A (ru) 2005-03-10
CN1551886A (zh) 2004-12-01
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
WO2002059264A3 (en) 2003-03-06
CZ20031983A3 (cs) 2005-07-13
EP1353937A4 (en) 2005-04-13
HUP0400775A2 (en) 2007-05-02
KR20030091952A (ko) 2003-12-03
IL156690A0 (en) 2004-01-04
RU2316564C2 (ru) 2008-02-10
BR0116763A (pt) 2004-03-09
NZ527173A (en) 2006-03-31
PL365758A1 (en) 2005-01-10
EP1353937A2 (en) 2003-10-22
JP2004524023A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
AU2001249760B2 (en) Mucin-1 specific binding members and methods of use thereof
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
KR20190028350A (ko) 인간 dlk1에 대한 항체 및 이의 용도
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
EP3495390A1 (en) Novel antibody against programmed cell death protein (pd-1), and use thereof
MXPA03005945A (es) Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos.
JP2005503756A5 (pt)
US20040202665A1 (en) Compositions and methods for therapeutic treatment
CA2491363A1 (en) Antibodies and uses thereof
US20110117602A1 (en) Human antibody capable of inducing apoptosis
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
US20040208877A1 (en) Antibodies and uses thereof
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
KR20190130604A (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued